Skip to main content
. 2017 Mar 1;8:14447. doi: 10.1038/ncomms14447

Figure 6. LCMV induces the strongest tumour regression compared with oncolytic viruses and PD1 blockade.

Figure 6

(a,b) Tumour diameter and survival of MOPC-tumour-bearing C57BL/6 mice (day −10) treated intratumourally (a) or intravenously (b) with LCMV, VSV-GP, rVACV or vehicle (n=5 per group). (c) Tumour diameter and survival of Sw480-tumour-bearing NOD/SCID mice treated i.t. with 2 × 106 PFU of LCMV, rVACV, VSV-GP or MOCK control (n=5 per group). (d) Immunofluorescence of tumours from MOPC-tumour-bearing mice (day −10) treated with or without 2 × 104 PFU LCMV peritumourally on day 0 (LCMV, green; red PD-L1; n=3 per group). (e) Tumour diameter and survival of MOPC-tumour-bearing C57BL/6 and Pdcd1–/– mice (day −10) treated with or without 2 × 104 PFU LCMV peritumourally on day 0 (n=5 per group). Data are shown as mean±s.e.m. and analysed by unpaired Student's t-test. Survival is shown in Kaplan–Meier method and analysed by log-rank test. NS, nonsignificant; *P<0.05, **P<0.01 and ***P<0.001; scale bar, 200 μm.